Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation

Neoplasma

Volumn 57, Issue 2, 2010, Pages 111-117

  Greslikova, H ^a   Zaoralova, R ^a   Filkova, H ^a,b   Nemec, P ^a   Oltova, A ^b   Kupska, R ^a   Rudolecka, P ^a   Smetana, J ^a   Pour, L ^a,b   Zahradova, L ^b   Krejci, M ^b   Buchler, T ^c   Adam, Z ^b   Hajek, R ^a,b   Kuglik, P ^a,b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

Author keywords

Chemotherapy; Chromosomal abnormalities; FISH; Multiple myeloma; Transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 13; CHROMOSOME ABERRATION; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CYTOGENETICS; DRUG MEGADOSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; AUTOTRANSPLANTATION; CANCER STAGING; CHROMOSOME 11; CHROMOSOME 14; CHROMOSOME 4; CHROMOSOME ANALYSIS; GENE TRANSLOCATION; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ADULT; AGED; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 4; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSLOCATION, GENETIC; TRANSPLANTATION, AUTOLOGOUS;

EID: 77953612139     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2010_02_111     Document Type: Article

References (29)

1. Catley L, Anderson K: Novel biologically based therapies for multiple myeloma. Business Briefing: US Oncology Review 2004, 1-6.
2. Merchionne F, Perosa F, Dammacco F: New therapies in multiple myeloma. Clin. Exp Med (2007) 7: 83-97. doi:10.1007/s10238-007-0134-y
3. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, et al.: High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-83. doi:10.1056/NEJMoa022340
4. Hajek R, Krejci M, Scudla V, Bacovsky J, Vytrasova M, et al.: Treatment of multiple myeloma with high-dose chemotherapy and peripheral blood stem cell transplantation followed by maintenance therapy with interferon alpha or by sequential maintenance therapy with interferon alpha and dexametazone randomized trial "4W" of Czech Myeloma Group. Klinicka onkologie, 2002, suplementum, 21-27.
5. Chang H, Qi C, Yi QL, Reece D, Stewart AK: p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood. 2005; 105 (1): 358-60. doi:10.1182/blood-2004-04-1363
6. Dalton WS, Bergsagel PL, Kuehl WM, Anderson KC and Harousseau JL: Multiple myeloma. Hematology, 2001 (1): 157-177. doi:10.1182/asheducation-2001.1.157
7. Kröger N, Schilling G, Einsele H, Liebisch P, Shimoni A, et al.:Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood. 2004; 103 (11): 4056-61. doi:10.1182/blood-2003-12-4435
8. Christensen JH, Abildgaard N, Plesner T, Nibe A, Nielsen O, et al.: Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark. Cancer Genet Cytogenet. 2007; 174 (2): 89-99. doi:10.1016/ j.cancergencyto.2006.11.015
9. Dewald GW, Therneau T, Larson D, Lee YK, Fink S, et al.: Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood. 2005; 106 (10): 3553-8. doi:10.1182/blood-2005-05-1981
10. Schmidt-Wolf IG, Glasmacher A, Hahn-Ast C, Jüttner A, Schnurr T, et al.: Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance. Cancer Genet Cytogenet. 2006; 167 (1): 20-5. doi:10.1016/j.cancergencyto.2005.10.016
11. Ross FM, Ibrahim AH, Vilain-Holmes A, Winfield MO, Chiecchio L, et al.: Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma (abstract). Leukemia. 2005; 19 (9): 1634-42. doi:10.1038/ sj.leu.2403857
12. Krejci M, Hajek R: Clinical trial CMG 2002-start of the new international multicentric randomized trial sponsored by Czech Myeloma Group. Klinicka onkologie, 2002, suplementum, 36-37.
13. Shaffer LG, Tommerup N. (eds). ISCN 2005: An International System for Human Cytogenetic Nomenclature; S. Karger, Basel 2005.
14. Ahmann GJ, Jalal SM, Juneau AL, Christensen ER, Hanson CA, et al.: A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet. 1998; 101 (1): 7-11. doi:10.1016/ S0165-4608(97)00058-7
15. Ross FM, Avet-Loiseau H, Drach J, Hernandez Rivas JM, Liebisch P, et al: European myeloma network recommendations for FISH in myeloma (Abstract). Haematologica. 2007;92(6) suppl 2: 100-101.
16. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, et al.: Biological and prognostic significance of interphase fluorescence in situ hybridisation detection of chromosome 13 abnormalities in multiple myeloma: an eastern cooperative oncology group study. Cancer research 2002; 62, 715-720.
17. Chen L, Li J, Xu W, Qiu H, Zhu Y, et al.: Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization. Exp Oncol 2007, 29, 2, 116-120.
18. Gutiérrez NC, Castellanos MV, Martín ML, Mateos MV, Hernández JM, et al.: Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia. 2007; 21 (1): 143-50. doi:10.1038/sj.leu.2404413
19. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, et al.: Genetic abnormalities and survival in multiple myeloma: the experience of the intergroupe francohpohne du myelome. Blood. 2007; 109 (8): 3489-95. doi:10.1182/blood-2006-08-040410
20. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, et al.: Clinical and biological implication of reccurent genomic aberrations in myeloma. Blood. 2003; 101 (11): 4569-75. doi:10.1182/blood-2002-10-3017
21. Terpos E, Eleutherakis-Papaiakovou V, Dimopoulos MA.: Clinical implications of chromosomal abnormalities in multiple myeloma. Leuk Lymphoma. 2006; 47(5):803-14. Review. doi:10.1080/10428190500464104
22. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C, et al.: Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001; 98 (7): 2229-38. doi:10.1182/blood. V98.7.2229
23. Pratt G.: Molecular aspect of multiple myeloma. J. Clin Pathol: Mol Pathol 2002, 55: 273-283. doi:10.1136/mp.55.5.273
24. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, et al.: Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunologica features and clinical presentation. Blood 2002; 99: 2185-2191. doi:10.1182/ blood.V99.6.2185
25. Chang H, Qi X, Trieu Y, Xu W, Reader JC, et al.: Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation. Br J Haematol. 2006; 135 (4): 486-91. doi:10.1111/j.1365-2141.2006.06325.x
26. Gutiérrez NC, García JL, Hernández JM, Lumbreras E, Castellanos M, et al.: Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood. 2004;104 (9): 2661-6. doi:10.1182/blood-2004-04-1319
27. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, et al.: Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006; 108 (5): 1724-32. doi:10.1182/blood-2006-03-009910
28. Nemec P, Zemanova Z, Greslikova H, Michalova K, Filkova H, et al.: Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. (manuscript).
29. Zemanova Z, Michalova K, Tajtlova J, Pavlistova L, Oltova A, et al.: Molecular cytogenetic analysis of immunofluorescence-labeled plasma cells of patients with multiple myeloma enrolled in CMG 2002 clinical trial. Klinicka onkologie, 2008; 21 supplement, 204-206.